Procoagulants and XXXX .

@entity1 @entity286 @entity1255 @entity167 @entity1252 @entity49 @entity29 @entity1003 @entity854 @entity74 @entity2530
OBJECTIVE: To study the relationship between hypofibrinolysis, @entity49 , and @entity2530 . We evaluated the frequency of abnormal concentrations of 9 coagulation factors in @entity1 diagnosed with @entity2530 . METHODS: Blood samples were drawn from 45 @entity1 diagnosed with @entity2530 . Etiologic associations included @entity1252 (n = 9), @entity29 (n = 1), corticosteroid therapy (n = 20), or history of heavy @entity167 (n = 4) or @entity286 (n = 3) use. No associated risk factors were identified in 5 @entity1 ; these individuals were labeled "idiopathic." The @entity1 cohort was matched to a similarly studied cohort of 40 healthy individuals without documented @entity2530 . The following factors were analyzed: plasminogen activator inhibitor (PAI-Fx), stimulated tissue plasminogen activator, lipoprotein (a), resistance to activated protein C, anticardiolipin antibodies (aCL IgG, IgM), protein C, protein S (free), and @entity1255 . RESULTS: Thirty-seven of the 45 @entity1 (82.2%) with @entity2530 were found to have at least one @entity1003 , versus 30% of controls (p < 0.0001). Twenty-one @entity1 (46.7%) were identified with 2 or more abnormal test results versus 2.5% of controls (p < 0.0001). @entity1 were more likely than controls to have high levels of the hypofibrinolytic plasminogen activator inhibitor activity (42% vs 3%; p < 0.0001), and high anticardiolipin antibody IgG (34% vs 10%; p = 0.008). At least one coagulation factor abnormality was detected in all 5 idiopathic @entity1 ; elevated aCL IgG and PAI-Fx were evident in 4 @entity1 . CONCLUSION: This study revealed a high incidence of thrombophilic and @entity854 in @entity1 with @entity2530 . These findings have major implications for the diagnosis as well as the treatment of this disease. Since some of these abnormalities may be the result of @entity74 , it may be possible to detect individuals at risk for development of this disease.
